Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency
By Dr. Matthew Watson
Internationally renown scientist Lee
Hood, winner of a National Medal of Science, violated the conflict of
interest policies of the California stem cell agency earlier this
year when he was involved in reviewing applications in a $40 million round to create genomics centers in California.
Lee Hood Institute of Systems Biology photo |
February violation in letters dated April 2 to the leadership of the
California Legislature. The letter (full text below)
said that Hood “agreed that there was a conflict of interest that
he had overlooked.”
million application that included participation by another eminent
scientist, Irv Weissman of Stanford University, and funding for facilities at
Stanford.
Weissman in Montana. In 2008, San Francisco Magazine, in a well-reported piece on the ballot measure that created the stem cell
agency, described the property as a ranch and Hood as Weissman's
“good buddy.” Hood has co-authored research papers with
Weissman. Both are on the scientific advisory board of Cellerant
Therapeutics, Inc., of San Carlos, Ca., a firm co-founded by
Weissman. Hood's nonprofit firm, Institute for Systems Biology in
Seattle, lists Stanford as a partner in the genetics of aging in humans. At Stanford, Weissman is director of the Institute
for Stem Cell Biology and Regenerative Medicine, whose research
involves aging. Weissman also serves on the Hood's institute's scientific advisory board.
yesterday by the California Stem Cell Report for his perspective on
the conflict of interest matter.
agency during the review. It was raised by another reviewer at the
end of the review, which, for the first time in CIRM history, failed
to conclude with a decision supporting any of the proposals.
Reviewers' comments have been sent back to applicants with another
review scheduled for November. The agency said Hood will not take
part in that session.
today that Hood's conflict was “clearly a case of a new reviewer
making an innocent error.” McCormack said it was not a violation of
the state's conflict of interest law. The agency's conflict policies
go beyond economic issues and deal with personal and professional
conflicts.
“Dr. Hood had not previously
participated in a meeting of the GWG(grant review group), and as a
result, he was not familiar with CIRM’s conflict of interest
policy, particularly the policy’s inclusion of 'personal' conflicts of interest. Thus, when he completed the conflict of
interest form for the Genomics Awards review, he inadvertently
neglected to indicate that he had a personal relationship with an
investigator who was involved in one component of a joint application
submitted by two institutions. Dr. Hood and the investigator are
close personal friends and their families own vacation property
together. Because of his personal relationship with the
investigator, Dr. Hood had a conflict of interest with respect to the
joint application under CIRM’s conflict of interest policies.”
been a guest at the Montana ranch, and whether he recruited Hood as a
reviewer. Last year, Trounson excused himself from participating in
public discussion of another application involving Weissman.
“Alan helps recruit many reviewers,
including in this case Dr. Hood, but he is not involved in assigning
reviewers to individual applications.”
was easily detectable in routine searches on the Internet, including
a Google search on the search term “lee hood irv weissman.” The first
two entries in that search yesterday turned up serious red flags.
sort of serious examination” of the confidential statements of
interests filed by reviewers prior to review sessions, McCormack said,
“Yes, we do a serious examination of
statements of interest from all our reviewers. However, this conflict
was not identified by the reviewer either in the financial disclosure
statement or identified in the conflict of interest list. Normally we
do not check Google for all possible combinations of 15 GWG reviewers
times about 200 individuals listed in these applications. That would
be about 3000 independent Google searches to identify a possible
conflict.”
that it plans to “amend its regulations to add greater clarity in
an effort to prevent future conflicts from arising and to augment its
efforts to educate reviewers, particularly new reviewers.”
questionable activities involving the stem cell agency, which is
trying to come up with a plan to sustain itself after its state
funding runs out in 2017(see here, here and here). The agency is
giving more-than-serious consideration to an effort to raise funds
from the private sector, which can lead to new and more difficult
ethical considerations than a state-funded agency would normally face.
demonstrate is that the $3 billion agency needs to give much more
thought, to put it mildly, to its policies ranging from conflicts of
interest to incompatible employee/director activities to the conduct
of top management in providing special treatment for donors.
interests of reviewers are not examined closely for their accuracy by
CIRM staff and attorneys. McCormack's remarks clearly indicate that
the agency does not think it has time to be sure that no conflicts
exist among its plethora of reviewers. That is precisely the reason
reviewers' statements of interests – economic, professional and
personal – should be made public rather than kept under wraps
by CIRM. Then, interested parties, presumably mainly applicants, can
check a panel of reviewers, if they wish, for conflicts in a
particular round. Obviously, the agency can and should withhold the
names of reviewers examining a specific application – the release
of the names on the panel in a given review session is sufficient.
evaluation subcommittee meets privately to discuss Alan Trounson's
performance. It appears to be the second part of an evaluation
process that began last October. Trounson's involvement with Weissman
and Hood -- and his actions in connection with a $21,630 gift from a member of the public, albeit a not-so-ordinary member of the public
-- should also be on the evaluation subcommittee agenda.
- 001 International Stem Cell Corporation Provides Strategic Update on its Skin Care Program [Last Updated On: April 9th, 2010] [Originally Added On: April 9th, 2010]
- 002 CSC news roundup 2010-04-11 [Last Updated On: April 12th, 2010] [Originally Added On: April 12th, 2010]
- 003 International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells [Last Updated On: April 14th, 2010] [Originally Added On: April 14th, 2010]
- 004 MicroRNA therapy could be a powerful tool to correct the CSC dysregulation? [Last Updated On: April 17th, 2010] [Originally Added On: April 17th, 2010]
- 005 CSC news links 2010-04-18 [Last Updated On: April 19th, 2010] [Originally Added On: April 19th, 2010]
- 006 Sessions on CSC Therapeutics at AACR10 [Last Updated On: April 27th, 2010] [Originally Added On: April 27th, 2010]
- 007 More about presentations at AACR10 [Last Updated On: May 2nd, 2010] [Originally Added On: May 2nd, 2010]
- 008 International Stem Cell Corporation Signs Financing Agreement [Last Updated On: May 6th, 2010] [Originally Added On: May 6th, 2010]
- 009 CSC news links 2010-05-08 [Last Updated On: May 9th, 2010] [Originally Added On: May 9th, 2010]
- 010 International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing [Last Updated On: May 12th, 2010] [Originally Added On: May 12th, 2010]
- 011 Generic drug a potential treatment for glioblastoma? [Last Updated On: May 14th, 2010] [Originally Added On: May 14th, 2010]
- 012 US Patent: Isolation and use of solid tumor stem cells [Last Updated On: May 18th, 2010] [Originally Added On: May 18th, 2010]
- 013 International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production [Last Updated On: May 19th, 2010] [Originally Added On: May 19th, 2010]
- 014 An evolving concept of CSC in tumor biology [Last Updated On: May 21st, 2010] [Originally Added On: May 21st, 2010]
- 015 International Stem Cell Corporation Moves International Cornea Development Program Forward [Last Updated On: May 26th, 2010] [Originally Added On: May 26th, 2010]
- 016 Phase I clinical trial of ICT-107 [Last Updated On: June 3rd, 2010] [Originally Added On: June 3rd, 2010]
- 017 CSCs responsible for metastasis identified [Last Updated On: June 6th, 2010] [Originally Added On: June 6th, 2010]
- 018 International Stem Cell Corporation's Parthenogenetic Stem Cell Patent is Approved by the United States Patent and Trademark Office [Last Updated On: June 9th, 2010] [Originally Added On: June 9th, 2010]
- 019 International Stem Cell Corporation Announces Company Update Conference Call. ISCO Chairman Kenneth Aldrich to Discuss 'Status of the Company' [Last Updated On: June 10th, 2010] [Originally Added On: June 10th, 2010]
- 020 Decitabine may target ovarian CSCs? [Last Updated On: June 14th, 2010] [Originally Added On: June 14th, 2010]
- 021 New Article from North County Times - BIOTECH: International Stem Cell Clears Debt, Gets Patent [Last Updated On: June 17th, 2010] [Originally Added On: June 17th, 2010]
- 022 Patent application: Levels of Oct1 as a method of identifying CSCs [Last Updated On: June 18th, 2010] [Originally Added On: June 18th, 2010]
- 023 OncoMed Has 'Wnt' in its Sails [Last Updated On: June 21st, 2010] [Originally Added On: June 21st, 2010]
- 024 International Stem Cell Corporation Names Charles J. Casamento to Board of Directors [Last Updated On: June 23rd, 2010] [Originally Added On: June 23rd, 2010]
- 025 International Stem Cell Corporation (ISCO.OB) Announces New Patent Issuance Under License Agreement [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 026 California Health Institute Interviews Jeffrey Janus - CEO of Lifeline Cell Technology [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 027 International Stem Cell Corporation - Excerpt from Agora Financial's Breakthrough Technology Alert by Patrick Cox [Last Updated On: July 1st, 2010] [Originally Added On: July 1st, 2010]
- 028 Melanoma-initiating cells identified [Last Updated On: July 2nd, 2010] [Originally Added On: July 2nd, 2010]
- 029 International Stem Cell Corporation and Sankara Nethralaya Launch Collaboration to Develop Stem Cell-Based Treatment for Corneal Vision Impairment [Last Updated On: July 8th, 2010] [Originally Added On: July 8th, 2010]
- 030 Two recent OA articles [Last Updated On: July 12th, 2010] [Originally Added On: July 12th, 2010]
- 031 Innovative Researcher Vlog [Last Updated On: July 16th, 2010] [Originally Added On: July 16th, 2010]
- 032 More about salinomycin [Last Updated On: July 19th, 2010] [Originally Added On: July 19th, 2010]
- 033 International Stem Cell Corporation Plans $10 Million Financing Through European Subsidiary [Last Updated On: July 23rd, 2010] [Originally Added On: July 23rd, 2010]
- 034 Irradiating brain's stem cell niche [Last Updated On: July 26th, 2010] [Originally Added On: July 26th, 2010]
- 035 Prostate CSCs sensitive to gamma-tocotrienol? [Last Updated On: July 27th, 2010] [Originally Added On: July 27th, 2010]
- 036 Researchers Study CSCs as Therapeutic Targets for Mesothelioma [Last Updated On: July 28th, 2010] [Originally Added On: July 28th, 2010]
- 037 International Stem Cell Corporation and Sristi Biosciences Enter Distribution Agreement for Lifeline Cell Technology's Brand of Human Cell Culture... [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 038 Disagreement about melanoma CSCs [Last Updated On: July 29th, 2010] [Originally Added On: July 29th, 2010]
- 039 Cell of origin for human prostate cancer [Last Updated On: August 1st, 2010] [Originally Added On: August 1st, 2010]
- 040 International Stem Cell Corporation - Breakthrough Technology Alert [Last Updated On: August 6th, 2010] [Originally Added On: August 6th, 2010]
- 041 Oxygen, hypoxia and the stem cell niche [Last Updated On: August 7th, 2010] [Originally Added On: August 7th, 2010]
- 042 Partnership Pays Off [Last Updated On: August 17th, 2010] [Originally Added On: August 17th, 2010]
- 043 Video: Summary of Recent Developments in Stem Cell and Regenerative Medicine from Kenneth Aldrich, Chairman of International Stem Cell Corporation [Last Updated On: August 18th, 2010] [Originally Added On: August 18th, 2010]
- 044 International Stem Cell Corporation Formalizes Stem Cell Based Eye Care Programs into Cytovis™ [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 045 International Stem cell Corporation Chairman Discusses Recent Stem Cell Research Funding Decision [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 046 International Stem Cell Corporation Not Adversely Affected by Stem Cell Research Funding Ban [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 047 A Primer on the Use of Stem Cells in Ophthalmology by Irving J. Arons [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 048 Kenneth Aldrich, Chairman and Co-Founder of International Stem Cell Corporation will be making two public appearances this week on behalf of ISCO. [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 049 International Stem Cell Corporation Reports Significant Progress Towards Creation of the First Bank of Immune-Matched Human Parthenogenetic Stem Cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 050 International Stem Cell Corporation and Insight Bioventures India Structure Indian Affiliate to Develop Stem Cell-Based Eye Care Therapeutics... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 051 ISCO to Present Data on Progress of Human Parthenogenetic Stem Cell Differentiation into Functional Liver Cells at the Annual Meeting... [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 052 Putative tumor-initiating progenitor cells predict poor lung cancer prognosis [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 053 Therapeutic implications of colon CSCs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 054 Selective targeting of neuroblastoma tumour-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 055 Two Open Access reviews [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 056 Isolation and killing of candidate CML stem cells by antibody targeting [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 057 Some breast cancer tumors may not originate from stem cells? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 058 On the low frequency of tumor-initiating cells [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 059 Must the last CML cell be killed? [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 060 Critical molecular pathways in CSCs of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 061 Insights into the stem cells of CML [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 062 International Stem Cell Corporation Announces Launch Plans for New Skin Care Products [Last Updated On: October 16th, 2010] [Originally Added On: October 16th, 2010]
- 063 International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation... [Last Updated On: October 26th, 2010] [Originally Added On: October 26th, 2010]
- 064 Notes from The Chairman Concerning ISCO Price Fluctuations [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 065 Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation's (ISCO) Therapeutic Research [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 066 International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 067 International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products [Last Updated On: December 10th, 2010] [Originally Added On: December 10th, 2010]
- 068 International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement [Last Updated On: December 15th, 2010] [Originally Added On: December 15th, 2010]
- 069 International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 070 International Stem Cell Corporation to Present Ethical and Technical Qualities of Human Parthenogenetic Stem Cells at the Center for Ethics in Science [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 071 Two new initiatives from the CSCC [Last Updated On: January 3rd, 2011] [Originally Added On: January 3rd, 2011]
- 072 A difference between normal and cancer SC biology in the nervous system [Last Updated On: January 7th, 2011] [Originally Added On: January 7th, 2011]
- 073 International Stem Cell Corporation Announces Company Update Conference Call [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 074 International Stem Cell Corporation Applauds Research Showing Parthenogenesis as a Potential Strategy for Treating Inherited Disease [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 075 International Stem Cell's Scientists in Collaboration with World Leading Stem Cell Experts Extend Understanding of Human Parthenogenetic Stem Cells... [Last Updated On: January 26th, 2011] [Originally Added On: January 26th, 2011]
- 076 International Stem Cell Corporation: A Multitude Of Potential Products From Its Parthenogenesis Technology by Jason Chew [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 077 International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development... [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 078 International Stem Cell Corporation: Note From The CEO Andrey Semechkin [Last Updated On: February 20th, 2011] [Originally Added On: February 20th, 2011]
- 079 "A Little Egg On the Face" - LifeLine Skin Care Stem Cell Cream Article [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
- 080 International Stem Cell Corporation Updates on 2010 Initial Product Launch of its Lifeline Skin Care Products [Last Updated On: March 6th, 2011] [Originally Added On: March 6th, 2011]
